Published in Ther Clin Risk Manag on March 01, 2007
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders. Behav Res Ther (2013) 0.83
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 45.33
Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry (1991) 8.37
Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. Circulation (1994) 2.50
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry (2002) 2.17
Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation (1994) 2.10
Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry (2006) 2.01
Phobic anxiety and risk of coronary heart disease and sudden cardiac death among women. Circulation (2005) 1.88
Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry (2002) 1.87
Urinary retention with venlafaxine-haloperidol combination. Pharmacopsychiatry (1997) 1.73
Mental disorders and asthma in the community. Arch Gen Psychiatry (2003) 1.71
Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry (2000) 1.68
Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuroscience (2002) 1.66
Children with prepubertal-onset major depressive disorder and anxiety grown up. Arch Gen Psychiatry (1999) 1.62
The cross-national epidemiology of panic disorder. Arch Gen Psychiatry (1997) 1.61
Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. Arch Gen Psychiatry (1989) 1.47
Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol (2004) 1.42
Panic and panic disorder in the United States. Am J Psychiatry (1994) 1.37
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA (2000) 1.29
Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol (1986) 1.26
Stress reactivity of the brain noradrenergic system in three rat strains differing in their neuroendocrine and behavioral responses to stress: implications for susceptibility to stress-related neuropsychiatric disorders. Neuroscience (2002) 1.21
Standardized assessment for panic disorder research. A conference report. Arch Gen Psychiatry (1994) 1.21
Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet (1999) 1.19
Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry (2006) 1.11
Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry (2005) 1.10
Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry (1988) 1.08
Remission and residual symptomatology in major depression. Psychopathology (1998) 1.07
Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol (1996) 1.03
Increased QT variability in patients with panic disorder and depression. Psychiatry Res (2000) 1.01
Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'. J Psychopharmacol (2001) 1.00
Functioning and well-being of patients with panic disorder. Am J Psychiatry (1996) 0.99
Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry (2006) 0.96
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry (2002) 0.95
Antidepressant discontinuation syndromes. Drug Saf (2001) 0.94
SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand (2002) 0.94
An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry (2001) 0.93
Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry (2003) 0.93
Shock-like sensations during venlafaxine withdrawal. Pharmacotherapy (2003) 0.91
The detection and consequences of anxiety in clinical depression. J Clin Psychiatry (1997) 0.90
Comorbidity of mood disorders: a longitudinal prospective study. Br J Psychiatry Suppl (1996) 0.89
Screening emergency room patients with atypical chest pain for depression and panic disorder. Int J Psychiatry Med (1988) 0.89
Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry (2005) 0.89
Treatment of anxiety disorders to remission. J Clin Psychiatry (2001) 0.88
Characteristics of people with infrequent panic attacks. J Abnorm Psychol (1985) 0.87
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry (2002) 0.87
A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiatry (1997) 0.87
A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull (2001) 0.86
Panic and suicidal ideation in primary care. Depress Anxiety (2001) 0.85
Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord (1989) 0.84
Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull (1996) 0.83
Paroxetine increases heart rate variability in panic disorder. J Clin Psychopharmacol (1997) 0.83
Quality of life and panic-related work disability in subjects with infrequent panic and panic disorder. J Clin Psychiatry (1997) 0.82
Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol (1997) 0.82
Higher lifetime prevalence of respiratory diseases in panic disorder? Am J Psychiatry (1991) 0.81
[Venlafaxine withdrawal syndrome: report of six cases and review of the literature]. Rev Med Interne (2000) 0.81
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol (2004) 0.79
Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. J Clin Pharmacol (1996) 0.78
Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. J Affect Disord (2002) 0.78
The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine. J Clin Pharmacol (1998) 0.78
Transient narcolepsy-cataplexy syndrome after discontinuation of the antidepressant venlafaxine. J Sleep Res (2005) 0.78
Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. J Clin Psychopharmacol (1993) 0.77
Effects of hyperventilation on heart rate and QT variability in panic disorder pre- and post-treatment. Psychiatry Res (2004) 0.77
Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol (1997) 0.77
Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet Hum Toxicol (1996) 0.77
Panic disorder and coping. Health Rep (2004) 0.76
Exertional dizziness and autonomic dysregulation. Laryngoscope (2002) 0.76
Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr Clin North Am (1993) 0.76
The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry (2012) 1.18
Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. J Clin Psychiatry (2007) 0.86
A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert Opin Pharmacother (2012) 0.78
Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review. BMC Psychiatry (2011) 0.76
Early Optimized Pharmacological Treatment in Patients With Depression and Chronic Pain. CNS Spectr (2022) 0.75